A Phase 1/2 interventional study of KTE-C19 and Atezolizumab in Refractory Diffuse Large B Cell Lymphoma, sponsored by Kite, A Gilead Company. Completed at 5 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-03-06.
Sponsored by Kite, A Gilead Company (part of Gilead Sciences) · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Lymphoma, Large B-Cell, Diffuse by Gilead Sciences — none open to participants now, none under way, none of them phase 3. Lymphoma, Large B-Cell, Diffuse · Gilead Sciences.
Among the 11 studies in Lymphoma, Large B-Cell, Diffuse by Gilead Sciences, this one is the 8th largest by enrollment of the 10 interventional ones that give a count, is the only one that started in 2016, is one of 4 in phase 1/2, and was the 8th registered.
1,870 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 359 are open to participants now.
Browse Lymphoma, Large B-Cell, Diffuse studies →None of the 11 studies in Lymphoma, Large B-Cell, Diffuse by Gilead Sciences is open now. The open studies under Lymphoma, Large B-Cell, Diffuse, anywhere →
Of the 266 Lymphoma, Large B-Cell, Diffuse studies recruiting now, 177 (67%) set no upper age limit and 51 (19%) stop at 75 or younger; 25 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 7 · Phase 3 3
First in 1997; this study’s year is marked. 1 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 37 is below the median of 44 across 1,501 interventional studies indexed under Lymphoma, Large B-Cell, Diffuse.
Median enrollment 63 across the 10 interventional studies. Of the 6 that completed or were terminated, 5 (83%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Kite, A Gilead Company, one of the names counted as Gilead Sciences. Under that name alone:
Kite, A Gilead Company is the lead sponsor of 40 studies on the registry; 8 are open to participants now.
Of its 19 completed or terminated interventional studies of FDA-regulated products, 16 (84%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 11 studies in Lymphoma, Large B-Cell, Diffuse by Gilead Sciences, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objective of phase 1 is to evaluate the safety of KTE-C19 and atezolizumab combination regimens.
The primary objective of phase 2 is to evaluate the efficacy of KTE-C19 and atezolizumab, as measured by complete response rate in participants with refractory diffuse large B-cell lymphoma (DLBCL).
Participants who received an infusion of KTE-C19 will complete the remainder of the 15 year follow-up assessments in a separate long-term follow-up study, KT-US-982-5968 (NCT05041309).
Key Inclusion Criteria:
Chemotherapy- disease, defined as one or more of the following:
Individuals must have received adequate prior therapy including at a minimum:
Key Exclusion Criteria:
Note: Other protocol defined Inclusion/Exclusion criteria may apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received conditioning chemotherapy consisting of 30 mg/m\^2 fludarabine and 500 mg/m\^2 cyclophosphamide intravenous (IV) infusion per day for 3 days followed by KTE-C19 IV infusion at a target dose of 2 x 10\^6 anti-CD19 chimeric antigen receptor (CAR) T cells/kg followed by 4 doses of atezolizumab (ATZ) (1200 mg/dose) IV infusion every 21 days, beginning 21 days following KTE-C19.
Biological: KTE-C19 · Biological: Atezolizumab · Drug: Cyclophosphamide · Drug: Fludarabine
Participants received conditioning chemotherapy consisting of 30 mg/m\^2 fludarabine and 500 mg/m\^2 cyclophosphamide IV infusion per day for 3 days followed by KTE-C19 IV infusion at a target dose of 2 x 10\^6 anti-CD19 CAR T cells/kg followed by 4 doses of ATZ (1200 mg/dose) IV infusion every 21 days, beginning 14 days following KTE-C19.
Biological: KTE-C19 · Biological: Atezolizumab · Drug: Cyclophosphamide · Drug: Fludarabine
Participants received conditioning chemotherapy consisting of 30 mg/m\^2 fludarabine and 500 mg/m\^2 cyclophosphamide IV infusion per day for 3 days followed by KTE-C19 IV infusion at a target dose of 2 x 10\^6 anti-CD19 CAR T cells/kg followed by 4 doses of ATZ (1200 mg/dose) IV infusion every 21 days, beginning 1 day following KTE-C19.
Biological: KTE-C19 · Biological: Atezolizumab · Drug: Cyclophosphamide · Drug: Fludarabine
Participants received conditioning chemotherapy consisting of 30 mg/m\^2 fludarabine and 500 mg/m\^2 cyclophosphamide IV infusion per day for 3 days followed by KTE-C19 IV infusion at a target dose of 2 x 10\^6 anti-CD19 CAR T cells/kg followed by 4 doses of ATZ (1200 mg/dose) IV infusion every 21 days, beginning 1 day following KTE-C19.
Biological: KTE-C19 · Biological: Atezolizumab · Drug: Cyclophosphamide · Drug: Fludarabine
A single infusion of KTE-C19 CAR-T cells administered intravenously
Also known as: Axicabtagene ciloleucel, Yescarta®
Administered intravenously
Administered intravenously
Administered intravenously
Phase 1: Number of Participants Experiencing Dose-Limiting Toxicities (DLTs)
A DLT was defined as the following KTE-C19-related or ATZ-related events with an onset from immediately after the first ATZ infusion through 21 days after the first ATZ infusion: Grade 4 hematologic toxicity lasting \> 30 days (except lymphopenia or B-cell aplasia); All KTE-C19- or ATZ-related Grade 3 non-hematologic toxicities lasting for \> 7 days and all KTE-C19- or ATZ-related Grade 4 non-hematologic toxicities regardless of duration.
Time frame: Baseline up to 21 days
Phase 1 and 2: Complete Response Rate (CRR)
CRR was assessed based on the International Working Group Revised Response Criteria for Malignant Lymphoma (Cheson, 2007), and was defined as the percentage of participants achieving a complete response (CR) as assessed by the study investigators. CR was defined as the complete resolution of all disease-related radiological abnormalities and the disappearance of all signs and symptoms related to the disease.
Time frame: From enrollment until first occurrence of CR or PR (maximum duration: 6.2 years)
Phase 1 and 2: Objective Response Rate (ORR)
ORR was assessed based on the International Working Group Revised Response Criteria for Malignant Lymphoma (Cheson, 2007), and was defined as the percentage of participants achieving a CR or partial response (PR) as assessed by the study investigators. CR was defined as the complete resolution of all disease-related radiological abnormalities and the disappearance of all signs and symptoms related to the disease. PR was defined at least a 50% decrease in sum of the product of the diameters (SPD) of up to six of the largest dominant nodes or nodal masses. Participants who did not meet the criteria for objective response by the analysis cutoff date were considered non-responders.
Time frame: From enrollment until first occurrence of CR or PR (maximum duration: 6.2 years)
Phase 1 and 2: Duration of Response (DOR)
DOR for participants who experienced an objective response was defined as the date of their first confirmed objective response (CR or PR) to disease progression per the revised International Working Group Response Criteria for Malignant Lymphoma (Cheson, 2007) or death regardless of cause. CR was defined as the complete resolution of all disease-related radiological abnormalities and the disappearance of all signs and symptoms related to the disease. PR was defined at least a 50% decrease in SPD of up to six of the largest dominant nodes or nodal masses. Disease progression was defined as any new lesion or increase by ≥ 50% of previously involved sites from nadir. The Kaplan-Meier approach was used to estimate DOR.
Time frame: From the date of first confirmed objective response (CR or PR) to disease progression or death regardless of cause (maximum duration: 6.2 years)
Phase 1 and 2: Progression-Free Survival (PFS)
PFS was defined as the time from the KTE-C19 infusion date to the date of disease progression per the revised International Working Group Response Criteria for Malignant Lymphoma (Cheson, 2007) or death from any cause. Disease progression was defined as any new lesion or increase by ≥ 50% of previously involved sites from nadir. The Kaplan-Meier approach was used to estimate PFS.
Time frame: From the date of first KTE-C19 infusion to disease progression or death regardless of cause (maximum duration: 6.2 years)
Phase 1 and 2: Overall Survival (OS)
OS was defined as the time from KTE-C19 infusion to the date of death from any cause. The Kaplan-Meier approach was used to estimate OS.
Time frame: From the date of first KTE-C19 infusion to the date of death regardless of cause (maximum duration: 6.2 years)
Phase 1 and 2: Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs)
An adverse event was defined as any untoward medical occurrence in a clinical trial participant. The event did not necessarily have a relationship with study treatment. Adverse events included worsening of a pre-existing medical condition. Worsening indicated that the pre-existing medical condition had increased in severity, frequency, and/or duration or had an association with a worse outcome. A pre-existing condition that had not worsened during the study or involved an intervention such as elective cosmetic surgery or a medical procedure while in study, was not considered an adverse event. TEAEs included all AEs with onset on or after initiation of axicabtagene ciloleucel.
Time frame: Up to 1.8 years
Phase 1 and 2: Percentage of Participants With Serum Chemistry Toxicity Grade Shifts to Grade 3 or Higher Resulting From Increased Parameter Values
Post axicabtagene ciloleucel infusion lab toxicities were reported. It included lab toxicities observed on or after the axicabtagene ciloleucel infusion date. ALT = alanine aminotransferase; ALP = alkaline phosphatase; AST = aspartate aminotransferase.
Time frame: Up to 1.8 years
Phase 1 and 2: Percentage of Participants With Serum Chemistry Toxicity Grade Shifts to Grade 3 or Higher Resulting From Decreased Parameter Values
Post axicabtagene ciloleucel infusion lab toxicities were reported. It included lab toxicities observed on or after the axicabtagene ciloleucel infusion date.
Time frame: Up to 1.8 years
Phase 1 and 2: Percentage of Participants With Hematology Toxicity Grade Shifts to Grade 3 or Higher Resulting From Increased Parameter Values
Post axicabtagene ciloleucel infusion lab toxicities were reported. It included lab toxicities observed on or after the axicabtagene ciloleucel infusion date.
Time frame: Up to 1.8 years
Phase 1 and 2: Percentage of Participants With Hematology Toxicity Grade Shifts to Grade 3 or Higher Resulting From Decreased Parameter Values
Post axicabtagene ciloleucel infusion lab toxicities were reported. It included lab toxicities observed on or after the axicabtagene ciloleucel infusion date.
Time frame: Up to 1.8 years
Phase 1 and 2: Peak Anti-CD19 CAR T-Cell (KTE-C19) Level (Maximum Observed Plasma Concentration) in Blood
Time frame: Pre-infusion (Baseline); Post-infusion: Days 7 (Phase 2), 14, 22 (Phase 2), 28 (Phase 2; optional), 35 (Phase 1, Cohort 3; optional), 43, 49 (optional), 64, 69 (optional), 94; long-term follow-up: every 3 months from Month 6 to Month 18, and Month 24
Phase 1 and 2: Percentage of Participants With Anti-KTE-C19 Antibodies
Time frame: Baseline (pre-conditioning chemotherapy); Day 0 (pre-KTE-C19 infusion); Days 1, 4, 7, 14, 22 , 28, Day 35, 49, 69, and 94 post-KTE-C19 infusion
Phase 1 and 2: Atezolizumab Levels in Blood
Time frame: Days 1, 14, 21, 22, 35, 42, 43, 56, 63, 64, 77, 84, 154, and 174
Phase 1 and 2: Percentage of Participants With Anti-Atezolizumab Antibodies
Time frame: Baseline (pre-conditioning chemotherapy); Day 0 (pre-KTE-C19 infusion); Days 1, 4, 7, 14, 22 , 28, Day 35, 49, 69, and 94 post-KTE-C19 infusion
Phase 1 and 2: Peak Serum Levels of C-Reactive Protein (CRP) in Blood
Time frame: Baseline (pre-conditioning chemotherapy); Day 0 (pre-KTE-C19 infusion); Days 1, 4, 7, and 14, and 22 , optional Day 28 (Phase 2) or Day 35 (Phase 1 Cohort 3), optional Day 49, optional Day 69, and Day 94 post-KTE-C19 infusion
Phase 1 and 2: Peak Serum Levels of C-X-C Motif Chemokine 10 (CXCL10), Interferon-Gamma (IFN-γ), Interleukin-1 Receptor Antagonist (IL-1RA), Interleukin (IL)-2, IL-6, IL-8, IL-15, and Tumor Necrosis Factor-Alpha (TNF-α) in Blood
Time frame: Baseline (pre-conditioning chemotherapy); Day 0 (pre-KTE-C19 infusion); Days 1, 4, 7, and 14, and 22 , optional Day 28 (Phase 2) or Day 35 (Phase 1 Cohort 3), optional Day 49, optional Day 69, and Day 94 post-KTE-C19 infusion
Phase 1 and 2: Peak Serum Levels of Ferritin in Blood
Time frame: Baseline (pre-conditioning chemotherapy); Day 0 (pre-KTE-C19 infusion); Days 1, 4, 7, and 14, and 22 , optional Day 28 (Phase 2) or Day 35 (Phase 1 Cohort 3), optional Day 49, optional Day 69, and Day 94 post-KTE-C19 infusion
Phase 1 and 2: Peak Serum Levels of Interleukin-2 Receptor Alpha (IL-2Rα) in Blood
Time frame: Baseline (pre-conditioning chemotherapy); Day 0 (pre-KTE-C19 infusion); Days 1, 4, 7, and 14, and 22 , optional Day 28 (Phase 2) or Day 35 (Phase 1 Cohort 3), optional Day 49, optional Day 69, and Day 94 post-KTE-C19 infusion
Participants were enrolled at study sites in the United States.
| Milestone | Phase 1 Cohort 1: KTE-C19 + ATZ (21 Days After KTE-C19) | Phase 1 Cohort 2: KTE-C19 + ATZ (14 Days After KTE-C19) | Phase 1 Cohort 3: KTE-C19 + ATZ (1 Day After KTE-C19) | Phase 2: KTE-C19 + ATZ (1 Day After KTE-C19) |
|---|---|---|---|---|
| Started | 3 | 4 | 7 | 23 |
| Completed | 1 | 0 | 1 | 0 |
| Not completed | 2 | 4 | 6 | 23 |
| Withdrew: Death | 1 | 1 | 2 | 13 |
| Withdrew: Lost to follow-up | 1 | 2 | 0 | 3 |
| Withdrew: Full consent withdrawal | 0 | 0 | 0 | 2 |
| Withdrew: Rolled over to long-term follow-up study | 0 | 0 | 3 | 4 |
| Withdrew: Investigator decision | 0 | 1 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 1 | 0 |
| Withdrew: Partial withdrawal of consent | 0 | 0 | 0 | 1 |
A DLT was defined as the following KTE-C19-related or ATZ-related events with an onset from immediately after the first ATZ infusion through 21 days after the first ATZ infusion: Grade 4 hematologic toxicity lasting \> 30 days (except lymphopenia or B-cell aplasia); All KTE-C19- or ATZ-related Grade 3 non-hematologic toxicities lasting for \> 7 days and all KTE-C19- or ATZ-related Grade 4 non-hematologic toxicities regardless of duration.
| Participants | Phase 1 Cohort 1: KTE-C19 + ATZ (21 Days After KTE-C19) | Phase 1 Cohort 2: KTE-C19 + ATZ (14 Days After KTE-C19) | Phase 1 Cohort 3: KTE-C19 + ATZ (1 Day After KTE-C19) |
|---|---|---|---|
| Phase 1: Number of Participants Experiencing Dose-Limiting Toxicities (DLTs) | 0 | 0 | 1 |
CRR was assessed based on the International Working Group Revised Response Criteria for Malignant Lymphoma (Cheson, 2007), and was defined as the percentage of participants achieving a complete response (CR) as assessed by the study investigators. CR was defined as the complete resolution of all disease-related radiological abnormalities and the disappearance of all signs and symptoms related to the disease.
| percentage of participants | Phase 1 (Cohort 3) + Phase 2: KTE-C19 + ATZ |
|---|---|
| Phase 1 and 2: Complete Response Rate (CRR) | 54 (34 to 72) |
ORR was assessed based on the International Working Group Revised Response Criteria for Malignant Lymphoma (Cheson, 2007), and was defined as the percentage of participants achieving a CR or partial response (PR) as assessed by the study investigators. CR was defined as the complete resolution of all disease-related radiological abnormalities and the disappearance of all signs and symptoms related to the disease. PR was defined at least a 50% decrease in sum of the product of the diameters (SPD) of up to six of the largest dominant nodes or nodal masses. Participants who did not meet the criteria for objective response by the analysis cutoff date were considered non-responders.
| percentage of participants | Phase 1 (Cohort 3) + Phase 2: KTE-C19 + ATZ |
|---|---|
| Phase 1 and 2: Objective Response Rate (ORR) | 75 (55 to 89) |
DOR for participants who experienced an objective response was defined as the date of their first confirmed objective response (CR or PR) to disease progression per the revised International Working Group Response Criteria for Malignant Lymphoma (Cheson, 2007) or death regardless of cause. CR was defined as the complete resolution of all disease-related radiological abnormalities and the disappearance of all signs and symptoms related to the disease. PR was defined at least a 50% decrease in SPD of up to six of the largest dominant nodes or nodal masses. Disease progression was defined as any new lesion or increase by ≥ 50% of previously involved sites from nadir. The Kaplan-Meier approach was used to estimate DOR.
| months | Phase 1 (Cohort 3) + Phase 2: KTE-C19 + ATZ |
|---|---|
| Phase 1 and 2: Duration of Response (DOR) | 41.4 (1.8 to NA) |
PFS was defined as the time from the KTE-C19 infusion date to the date of disease progression per the revised International Working Group Response Criteria for Malignant Lymphoma (Cheson, 2007) or death from any cause. Disease progression was defined as any new lesion or increase by ≥ 50% of previously involved sites from nadir. The Kaplan-Meier approach was used to estimate PFS.
| months | Phase 1 (Cohort 3) + Phase 2: KTE-C19 + ATZ |
|---|---|
| Phase 1 and 2: Progression-Free Survival (PFS) | 9 (3.1 to NA) |
OS was defined as the time from KTE-C19 infusion to the date of death from any cause. The Kaplan-Meier approach was used to estimate OS.
| months | Phase 1 (Cohort 3) + Phase 2: KTE-C19 + ATZ |
|---|---|
| Phase 1 and 2: Overall Survival (OS) | 32.2 (11.6 to NA) |
An adverse event was defined as any untoward medical occurrence in a clinical trial participant. The event did not necessarily have a relationship with study treatment. Adverse events included worsening of a pre-existing medical condition. Worsening indicated that the pre-existing medical condition had increased in severity, frequency, and/or duration or had an association with a worse outcome. A pre-existing condition that had not worsened during the study or involved an intervention such as elective cosmetic surgery or a medical procedure while in study, was not considered an adverse event. TEAEs included all AEs with onset on or after initiation of axicabtagene ciloleucel.
| percentage of participants | Phase 1 Cohort 1: KTE-C19 + ATZ (21 Days After KTE-C19) | Phase 1 Cohort 2: KTE-C19 + ATZ (14 Days After KTE-C19) | Phase 1 Cohort 3: KTE-C19 + ATZ (1 Day After KTE-C19) | Phase 2: KTE-C19 + ATZ (1 Day After KTE-C19) |
|---|---|---|---|---|
| Phase 1 and 2: Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs) | 100 | 100 | 100 | 100 |
Post axicabtagene ciloleucel infusion lab toxicities were reported. It included lab toxicities observed on or after the axicabtagene ciloleucel infusion date. ALT = alanine aminotransferase; ALP = alkaline phosphatase; AST = aspartate aminotransferase.
| percentage of participants | Phase 1 Cohort 1: KTE-C19 + ATZ (21 Days After KTE-C19) | Phase 1 Cohort 2: KTE-C19 + ATZ (14 Days After KTE-C19) | Phase 1 Cohort 3: KTE-C19 + ATZ (1 Day After KTE-C19) | Phase 2: KTE-C19 + ATZ (1 Day After KTE-C19) |
|---|---|---|---|---|
| Shift to Grade 3 ALT | 0 | 0 | 0 | 5 |
| Shift to Grade 4 ALT | 0 | 0 | 0 | 5 |
| Shift to Grade 3 ALP | 0 | 0 | 0 | 14 |
| Shift to Grade 3 AST | 0 | 0 | 0 | 9 |
| Shift to Grade 4 AST | 0 | 0 | 0 | 5 |
| Shift to Grade 3 bilirubin | 0 | 0 | 0 | 9 |
| Shift to Grade 4 calcium | 0 | 0 | 0 | 5 |
| Shift to Grade 3 creatinine | 0 | 0 | 0 | 9 |
| Shift to Grade 4 creatinine | 0 | 0 | 0 | 5 |
| Shift to Grade 3 direct bilirubin | 33 | 33 | 17 | 14 |
| Shift to Grade 3 glucose | 0 | 0 | 0 | 18 |
| Shift to Grade 4 glucose | 0 | 0 | 0 | 14 |
Post axicabtagene ciloleucel infusion lab toxicities were reported. It included lab toxicities observed on or after the axicabtagene ciloleucel infusion date.
| percentage of participants | Phase 1 Cohort 1: KTE-C19 + ATZ (21 Days After KTE-C19) | Phase 1 Cohort 2: KTE-C19 + ATZ (14 Days After KTE-C19) | Phase 1 Cohort 3: KTE-C19 + ATZ (1 Day After KTE-C19) | Phase 2: KTE-C19 + ATZ (1 Day After KTE-C19) |
|---|---|---|---|---|
| Shift to Grade 3 albumin | 33 | 0 | 0 | 9 |
| Shift to Grade 3 calcium | 33 | 0 | 0 | 5 |
| Shift to Grade 4 calcium | 0 | 0 | 0 | 18 |
| Shift to Grade 3 phosphate | 67 | 67 | 33 | 36 |
| Shift to Grade 4 phosphate | 0 | 0 | 0 | 36 |
| Shift to Grade 3 potassium | 0 | 0 | 0 | 14 |
| Shift to Grade 3 sodium | 67 | 0 | 17 | 14 |
| Shift to Grade 4 glucose | 0 | 0 | 17 | 0 |
Post axicabtagene ciloleucel infusion lab toxicities were reported. It included lab toxicities observed on or after the axicabtagene ciloleucel infusion date.
| percentage of participants | Phase 1 Cohort 1: KTE-C19 + ATZ (21 Days After KTE-C19) | Phase 1 Cohort 2: KTE-C19 + ATZ (14 Days After KTE-C19) | Phase 1 Cohort 3: KTE-C19 + ATZ (1 Day After KTE-C19) | Phase 2: KTE-C19 + ATZ (1 Day After KTE-C19) |
|---|---|---|---|---|
| Phase 1 and 2: Percentage of Participants With Hematology Toxicity Grade Shifts to Grade 3 or Higher Resulting From Increased Parameter Values | 0 | 0 | 0 | 0 |
Post axicabtagene ciloleucel infusion lab toxicities were reported. It included lab toxicities observed on or after the axicabtagene ciloleucel infusion date.
| percentage of participants | Phase 1 Cohort 1: KTE-C19 + ATZ (21 Days After KTE-C19) | Phase 1 Cohort 2: KTE-C19 + ATZ (14 Days After KTE-C19) | Phase 1 Cohort 3: KTE-C19 + ATZ (1 Day After KTE-C19) | Phase 2: KTE-C19 + ATZ (1 Day After KTE-C19) |
|---|---|---|---|---|
| Shift to Grade 3 hemoglobin | 100 | 67 | 83 | 59 |
| Shift to Grade 3 leukocytes | 0 | 0 | 33 | 18 |
| Shift to Grade 4 leukocytes | 100 | 100 | 67 | 77 |
| Shift to Grade 4 lymphocytes | 100 | 100 | 100 | 86 |
| Shift to Grade 3 neutrophils | 0 | 33 | 17 | 14 |
| Shift to Grade 4 neutrophils | 100 | 67 | 83 | 73 |
| Shift to Grade 3 platelets | 33 | 0 | 17 | 18 |
| Shift to Grade 4 platelets | 33 | 67 | 17 | 32 |
| cells/μL | Phase 1 Cohort 1: KTE-C19 + ATZ (21 Days After KTE-C19) | Phase 1 Cohort 2: KTE-C19 + ATZ (14 Days After KTE-C19) | Phase 1 Cohort 3: KTE-C19 + ATZ (1 Day After KTE-C19) | Phase 2: KTE-C19 + ATZ (1 Day After KTE-C19) |
|---|---|---|---|---|
| Phase 1 and 2: Peak Anti-CD19 CAR T-Cell (KTE-C19) Level (Maximum Observed Plasma Concentration) in Blood | 86.87 ± 67.17 | 167.88 ± 91.58 | 60.71 ± 70.66 | 60.22 ± 60.24 |
| percentage of participants | Phase 1 Cohort 1: KTE-C19 + ATZ (21 Days After KTE-C19) | Phase 1 Cohort 2: KTE-C19 + ATZ (14 Days After KTE-C19) | Phase 1 Cohort 3: KTE-C19 + ATZ (1 Day After KTE-C19) | Phase 2: KTE-C19 + ATZ (1 Day After KTE-C19) |
|---|---|---|---|---|
| Phase 1 and 2: Percentage of Participants With Anti-KTE-C19 Antibodies | 0 | 0 | 0 | 0 |
| ng/mL | Phase 1 Cohort 1: KTE-C19 + ATZ (21 Days After KTE-C19) | Phase 1 Cohort 2: KTE-C19 + ATZ (14 Days After KTE-C19) | Phase 1 Cohort 3: KTE-C19 + ATZ (1 Day After KTE-C19) | Phase 2: KTE-C19 + ATZ (1 Day After KTE-C19) |
|---|---|---|---|---|
| Day 1 | — | — | 373000 ± 65300 | 328000 ± 89100 |
| Day 14 | — | 435000 ± 61500 | — | — |
| Day 21 | 403000 ± 46100 | — | — | — |
| Day 22 | — | — | 73900 ± 27900 | 110000 ± 126000 |
| Day 35 | — | 84200 ± 14300 | — | — |
| Day 42 | 98800 ± 16500 | — | — | — |
| Day 43 | — | — | 138000 ± 78700 | 136000 ± 69900 |
| Day 56 | — | 176000 ± 2828.43 | — | — |
| Day 63 | 175000 ± 7505.55 | — | — | — |
| Day 64 | — | — | 159000 ± 91600 | 185000 ± 88700 |
| Day 77 | — | 240000 ± 33000 | — | — |
| Day 84 | 209000 ± 24800 | — | — | — |
| Day 154 | — | — | 13600 | 66800 ± 58900 |
| Day 174 | 91000 | — | — | — |
| percentage of participants | Phase 1 Cohort 1: KTE-C19 + ATZ (21 Days After KTE-C19) | Phase 1 Cohort 2: KTE-C19 + ATZ (14 Days After KTE-C19) | Phase 1 Cohort 3: KTE-C19 + ATZ (1 Day After KTE-C19) | Phase 2: KTE-C19 + ATZ (1 Day After KTE-C19) |
|---|---|---|---|---|
| Phase 1 and 2: Percentage of Participants With Anti-Atezolizumab Antibodies | 0 | 0 | 0 | 0 |
| mg/L | Phase 1 (Cohort 3) + Phase 2: KTE-C19 + ATZ |
|---|---|
| Phase 1 and 2: Peak Serum Levels of C-Reactive Protein (CRP) in Blood | 174.03 (51.78 to 496.00) |
| pg/mL | Phase 1 (Cohort 3) + Phase 2: KTE-C19 + ATZ |
|---|---|
| CXCL 10 | 2000.00 (444.80 to 2000.00) |
| IFN-γ | 587.80 (15.60 to 1876.00) |
| IL-1RA | 2469.60 (541.40 to 9000.00) |
| IL-2 | 17.55 (1.80 to 152.70) |
| IL-6 | 121.55 (4.30 to 976.00) |
| IL-8 | 180.65 (18.60 to 750.00) |
| IL-15 | 48.95 (19.10 to 161.20) |
| TNF-α | 8.20 (3.40 to 55.50) |
| ng/mL | Phase 1 (Cohort 3) + Phase 2: KTE-C19 + ATZ |
|---|---|
| Phase 1 and 2: Peak Serum Levels of Ferritin in Blood | 1427.39 (219.92 to 23100) |
| ng/mL | Phase 1 (Cohort 3) + Phase 2: KTE-C19 + ATZ |
|---|---|
| Phase 1 and 2: Peak Serum Levels of Interleukin-2 Receptor Alpha (IL-2Rα) in Blood | 17.75 (3.45 to 57.77) |
Collected over Adverse Events: Up to 1.8 years; All-Cause Mortality: Enrollment up to 30 days after completion of the final dose of atezolizumab, or 24 months after the KTE-C19 infusion or until disease progression, whichever was longer (maximum duration: 6.2 years). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Phase 1 Cohort 1: KTE-C19 + ATZ (21 Days After KTE-C19) | 2/3 (66.7%) | 3/3 (100%) | 3/3 (100%) |
| Phase 1 Cohort 2: KTE-C19 + ATZ (14 Days After KTE-C19) | 1/4 (25%) | 2/3 (66.7%) | 3/3 (100%) |
| Phase 1 Cohort 3: KTE-C19 + ATZ (1 Day After KTE-C19) | 2/7 (28.6%) | 3/6 (50%) | 6/6 (100%) |
| Phase 2: KTE-C19 + ATZ (1 Day After KTE-C19) | 14/23 (60.9%) | 15/22 (68.2%) | 22/22 (100%) |
| Event | Phase 1 Cohort 1: KTE-C19 + ATZ (21 Days After KTE-C19) | Phase 1 Cohort 2: KTE-C19 + ATZ (14 Days After KTE-C19) | Phase 1 Cohort 3: KTE-C19 + ATZ (1 Day After KTE-C19) | Phase 2: KTE-C19 + ATZ (1 Day After KTE-C19) |
|---|---|---|---|---|
| EncephalopathyNervous system disorders | 2/3 | 1/3 | 1/6 | 4/22 |
| AnaemiaBlood and lymphatic system disorders | 0/3 | 1/3 | 1/6 | 0/22 |
| Lower gastrointestinal haemorrhageGastrointestinal disorders | 0/3 | 1/3 | 0/6 | 0/22 |
| Obstruction gastricGastrointestinal disorders | 0/3 | 1/3 | 0/6 | 0/22 |
| PneumoniaInfections and infestations | 1/3 | 0/3 | 0/6 | 1/22 |
| Malignant melanomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/3 | 0/3 | 0/6 | 0/22 |
| SeizureNervous system disorders | 0/3 | 1/3 | 0/6 | 1/22 |
| AspirationRespiratory, thoracic and mediastinal disorders | 0/3 | 1/3 | 0/6 | 0/22 |
| HypoxiaRespiratory, thoracic and mediastinal disorders | 1/3 | 0/3 | 0/6 | 1/22 |
| PneumothoraxRespiratory, thoracic and mediastinal disorders | 0/3 | 1/3 | 0/6 | 0/22 |
| Event | Phase 1 Cohort 1: KTE-C19 + ATZ (21 Days After KTE-C19) | Phase 1 Cohort 2: KTE-C19 + ATZ (14 Days After KTE-C19) | Phase 1 Cohort 3: KTE-C19 + ATZ (1 Day After KTE-C19) | Phase 2: KTE-C19 + ATZ (1 Day After KTE-C19) |
|---|---|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 2/3 | 3/3 | 4/6 | 13/22 |
| FatigueGeneral disorders | 2/3 | 3/3 | 4/6 | 11/22 |
| PyrexiaGeneral disorders | 3/3 | 3/3 | 6/6 | 21/22 |
| EncephalopathyNervous system disorders | 3/3 | 1/3 | 2/6 | 7/22 |
| HypotensionVascular disorders | 3/3 | 2/3 | 4/6 | 9/22 |
| NauseaGastrointestinal disorders | 1/3 | 2/3 | 5/6 | 8/22 |
| NeutropeniaBlood and lymphatic system disorders | 2/3 | 1/3 | 1/6 | 5/22 |
| Sinus tachycardiaCardiac disorders | 1/3 | 1/3 | 4/6 | 10/22 |
| Abdominal painGastrointestinal disorders | 2/3 | 2/3 | 2/6 | 3/22 |
| ConstipationGastrointestinal disorders | 2/3 | 2/3 | 0/6 | 4/22 |
The Safety Analysis Set included all participants treated with any dose of KTE-C19.
| Age, Categorical(Participants) | Phase 1 Cohort 1: KTE-C19 + ATZ (21 Days After KTE-C19) | Phase 1 Cohort 2: KTE-C19 + ATZ (14 Days After KTE-C19) | Phase 1 Cohort 3: KTE-C19 + ATZ (1 Day After KTE-C19) | Phase 2: KTE-C19 + ATZ (1 Day After KTE-C19) | Total |
|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 2 | 2 | 6 | 18 | 28 |
| >=65 years | 1 | 1 | 0 | 4 | 6 |
| Age, Continuous(years) | Phase 1 Cohort 1: KTE-C19 + ATZ (21 Days After KTE-C19) | Phase 1 Cohort 2: KTE-C19 + ATZ (14 Days After KTE-C19) | Phase 1 Cohort 3: KTE-C19 + ATZ (1 Day After KTE-C19) | Phase 2: KTE-C19 + ATZ (1 Day After KTE-C19) | Total |
|---|---|---|---|---|---|
| Mean | 56.0 ± 14.80 | 42.7 ± 19.50 | 53.2 ± 6.18 | 58.4 ± 7.40 | 56 ± 9.9 |
| Sex: Female, Male(Participants) | Phase 1 Cohort 1: KTE-C19 + ATZ (21 Days After KTE-C19) | Phase 1 Cohort 2: KTE-C19 + ATZ (14 Days After KTE-C19) | Phase 1 Cohort 3: KTE-C19 + ATZ (1 Day After KTE-C19) | Phase 2: KTE-C19 + ATZ (1 Day After KTE-C19) | Total |
|---|---|---|---|---|---|
| Female | 0 | 2 | 4 | 8 | 14 |
| Male | 3 | 1 | 2 | 14 | 20 |
| Ethnicity (NIH/OMB)(Participants) | Phase 1 Cohort 1: KTE-C19 + ATZ (21 Days After KTE-C19) | Phase 1 Cohort 2: KTE-C19 + ATZ (14 Days After KTE-C19) | Phase 1 Cohort 3: KTE-C19 + ATZ (1 Day After KTE-C19) | Phase 2: KTE-C19 + ATZ (1 Day After KTE-C19) | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 1 | 1 | 0 | 1 | 3 |
| Not Hispanic or Latino | 2 | 2 | 6 | 20 | 30 |
| Unknown or Not Reported | 0 | 0 | 0 | 1 | 1 |
| Race/Ethnicity, Customized(Participants) | Phase 1 Cohort 1: KTE-C19 + ATZ (21 Days After KTE-C19) | Phase 1 Cohort 2: KTE-C19 + ATZ (14 Days After KTE-C19) | Phase 1 Cohort 3: KTE-C19 + ATZ (1 Day After KTE-C19) | Phase 2: KTE-C19 + ATZ (1 Day After KTE-C19) | Total |
|---|---|---|---|---|---|
| Asian | 1 | 0 | 1 | 3 | 5 |
| White | 2 | 3 | 5 | 18 | 28 |
| Other | 0 | 0 | 0 | 1 | 1 |
| Region of Enrollment(Participants) | Phase 1 Cohort 1: KTE-C19 + ATZ (21 Days After KTE-C19) | Phase 1 Cohort 2: KTE-C19 + ATZ (14 Days After KTE-C19) | Phase 1 Cohort 3: KTE-C19 + ATZ (1 Day After KTE-C19) | Phase 2: KTE-C19 + ATZ (1 Day After KTE-C19) | Total |
|---|---|---|---|---|---|
| United States | 3 | 3 | 6 | 22 | 34 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at https://www.gilead.com/science-and-medicine/research/clinical-trials-transparency-and-data-sharing-policy
Supporting information: Study protocol, Statistical analysis plan
Time frame: 18 months after study completion
Access criteria: A secured external environment with username, password, and RSA code.
Data sharing details ↗ · www.gilead.com
Ran from Sep 2016 to primary completion in Jan 2023, 75 months.
Of 51 industry-sponsored phase 1/2 interventional studies under Lymphoma, Large B-Cell, Diffuse, half reached primary completion within 75 months of starting (the median), counting those still running; a quarter within 54 and three quarters within 99. This study's 75 months is close to that.
Counting every sponsor, half of 108 studies reached it within 70 months; a quarter within 50 and three quarters within 98.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Axicabtagene ciloleucel
Lymphoma, Large B-Cell, Diffuse →